Introduction
The term minimal residual disease (MRD) denotes the miniscule remnants of a cancer remaining after cytoreduction, which are not recognizable by standard techniques. This relatively novel concept has proven highly relevant in hematological malignancies such as acute leukemias, where high complete remission (CR) rates may be followed by relapses in more than half of the patients. 1 In this setting, quantitative RT-PCR (qPCR) has emerged as an exciting tool, partly because of its extremely high dynamic range (usually exceeding 5 logs), and partly because it is amenable to detection of disease-specific alterations in these patients. Leukemia-specific rearrangements, point mutations, gene duplications and overexpression of genes can be detected by qPCR, in some instances with a sensitivity exceeding 1:100 000 leukemic cells. 2 An added advantage of the qPCR method is that it can be standardized, as evidenced, for example, by multicenter efforts delineating the optimal control genes to include in the assays, as well as the definition of universally recognized protocols and primer designs. [3] [4] [5] [6] [7] [8] Although these features constitute great advantages for the clinical integration of qPCR assays, major differences between individual laboratories in terms of variation in the qPCR procedures, together with differences in calculation of results and presentation of MRD data both in daily routine and in research, has hampered determination of the clinical use of MRD assessment in multicenter settings and the development of this technology to guide treatment approach. Given that this variability is a crucial limitation to the dissemination of this methodology, it was therefore decided under the auspices of the European LeukemiaNet (ELN) Minimal Residual Disease Work Package (WP12) to design a software package, which would enable individual centers conducting qPCR for MRD measurements to collect and express data in a standardized manner. Accommodating local differences in qPCR hardware and MRD calculation methods while retaining different options for expressing and displaying data within the European network, all presented major challenges that were surmounted in the creation of a highly flexible and adaptable software package. Here we describe the features of the MRD-reporting program and its validation through an extensive quality control (QC) study involving laboratories throughout Europe.
Materials and methods

MRD-reporting software
The software, which was developed in a close collaboration between a steering committee established as part of the ELN WP12 (MØ, CGN, DG and PH) and the IT company Langtved Data (Langtved Data Ltd, Ringsted, Denmark) was designed to accommodate local handling and reporting of MRD data while facilitating harmonization of MRD data irrespective of differences in qPCR platform, and with different standard options for MRD and sensitivity calculation. As outlined in Figure 1 , qPCR data (sample IDs, target genes, Ct values and copy-number information in case of absolute quantification) exported as a text file from the qPCR equipment are imported to the database and linked via the sample IDs to the corresponding patient. The MRD levels can now be calculated and displayed by choosing the report with the MRD formula and graphical layout of interest. Finally, comments and conclusions can be added to complete the report. A detailed description of the software including the requirements in terms of hardware, operating system and network structure is provided in Supplementary MethodsFSoftware design.
Quality control study design
To validate the software and provide proof-of-principle for its applicability in general use and in multicenter studies, we designed a two-step QC study. The purpose of step one (QC I) was to provide an overall validation of the package by software installation and testing of basic functionalities, such as entering patient-and sample-specific information into the database and importing the corresponding qPCR data from the text file generated from the qPCR run. Moreover, using different MRD calculation and reporting features for the same data sets tested the robustness of the MRD evaluation module. Test materials comprised five consecutive peripheral blood (PB) samples from a chronic myeloid leukemia (CML) patient (BCR-ABL þ ), five consecutive PB samples from an acute myeloid leukemia (AML) patient (CBFb-MYH11 þ and overexpressing the WT1 gene), as well as a K562 cell line sample. QC I included eight test laboratories with different previous experience of using earlier versions of the software, ranging from comprehensive and/or extensive experience (laboratories E and F), to limited (laboratories A, B and C) or no previous experience whatsoever (laboratories D, G and H). The purpose of QC step two (QC II) was to demonstrate the usefulness of the software for harmonizing MRD data in multicenter studies. In CML, a recent initiative within the European Treatment and Outcome Study (EUTOS) was undertaken to establish an international scale for comparison of molecular response rates between laboratories and between clinical trials. 9 Thereby, several laboratories have obtained an international scale (IS) conversion factor (CF) that allows for reporting of CML MRD data in a common scale, independently of the local choice of sample processing and qPCR methodology. 9 Five of the laboratories participating in this study had obtained an IS CF (C, D, F, G and H). In QC II, the five CML PB samples used as test material were processed centrally by laboratory F until storage in lysis buffer according to the routine procedures in the five test laboratories. Further RNA purification and qPCR procedures were carried out locally according to the conditions underlying the IS CFs. The details of the QC study may be found in Supplementary MethodsFQC study design.
Software testing
In each laboratory, the software was installed as a single-PC application. Successful creation in the database of patient files with consecutive MRD samples, followed by platform-specific import of qPCR data from text files, was a precondition for further software testing and report generation. In QC I the software was used to generate 16 specified reports covering central software functions, including different choices of MRD calculation method and graphic presentation modes, generation of patient reports, as well as tabular lists of MRD data. A thorough description of the reports can be found in Supplementary MethodsFQC study design and Supplementary  Table 1 . The reports were sent to laboratory F as read-only files for centralized evaluation. Moreover, text files with primary data from the qPCR hardware were included for elucidation of aberrant results. Formulae for MRD and sensitivity calculation together with criteria for defining a sample as MRD positive or negative are provided in Supplementary Table 2 . In QC II, four reports were generated for analysis, showing an MRD graph or results list before and after application of the CF in MRD calculations, respectively.
As the participating laboratories were enrolled over a period of time, they received the software at different time points. Consequently, software glitches encountered in the first laboratories were corrected before the software was sent to the next laboratories. Given this, for the QC study there were few minor differences between the software versions tested by the participants. To verify the overall evaluation of the QC study, and to be able to compare the MRD results while eliminating possible differences due to lack of experience with the software or incomplete adherence to the designations in the QC protocol, all primary qPCR data generated in QC I were reanalyzed in laboratory F using the latest version of the software (version number 8.6, release 5, build 100).
Results
QC IFevaluation of software performance
QC I aimed at testing basic software functions such as installation and entry of data into the database, as well as the function of a number of central MRD-reporting features. Different degrees of support were required from Langtved Data, Standardized reporting of MRD data by MRD-reporting software M Østergaard et al by telephone or online guidance, either during the installation process or for metabase adjustment for successful import of data to the database. These requirements were generally related to local computer operating system settings. There was no need for software support for further use of the program. All participants successfully created patient files in the database. The 16 requested reports were returned by all participants except one (Laboratory A), where six reports were missing because of failed export of qPCR CML data from the qPCR equipment ( Figure 2) . The reports revealed a few software glitches, some of which by nature affected more than one report, as well as several laboratories. These glitches were corrected during the course of QC I, as revealed by the lack of software-related errors in Laboratory H, which used the latest software version. A detailed overview of the success rates of report generation according to previous experience with the MRD-reporting software, together with the composition of the 16 reports can be found in Supplementary Table 1 . Supplementary Figure 2 shows as an example of software-generated MRD results a comparison between the participating laboratories of the MRD graph from report number 5, showing single-graph displays of the combined CBFb-MYH11 and WT1 results in the studied AML patient. To further compare the results between the laboratories, MRD values were entered in Excel to superimpose the MRD curves for relative and absolute quantification, respectively, for each of the three target genes (Supplementary Figure 3) . Most deviations from the reference laboratory (F) thus revealed could after examination of the text files with primary qPCR data be explained by incorrect use of the software because of lack of adherence to the QC study protocol and/or lack of experience (described in the legend to Supplementary Figure 3) . We therefore conclude that although initially a certain degree of support may be required primarily to ensure compatibility with local computer settings, the corrected software is fully functional and suited for flexible expression of MRD results.
QC IFconcordance of MRD results between laboratories
The centralized reanalysis of the qPCR data with the latest software version allowed us to evaluate the consistency of the MRD results that could be generated from all of the eight participating laboratories while consistently adhering to the specifications of the QC I protocol (Figure 3) . Generally, the MRD results were highly concordant between the laboratories. The overall range of sample-specific coefficients of variation (CVs) among the eight laboratories was 21-201%, being generally highest in samples with the lowest MRD level, which is in accordance with a larger variability in the Ct values of qPCR reactions with low target gene-copy numbers. 10 
QC IIFusage of CML IS CF in MRD software
A number of possibilities to adjust the MRD and sensitivity calculation formulae have been included in the software. Such adjustments, for example, allowance for differing PCR efficiencies may be made either at a general level, by introducing a correction factor to the calculation formulae, or, at a samplespecific level, by adding a correction factor on a single sample in the application window. This feature was used in QC II for adjustment of data with the CML CFs (Figure 4) . Before CF adjustment, laboratories C and F reported their MRD results as K562-normalized relative values, normalizing to ABL, B2M and GUS as control genes. Laboratories D and H reported absolute values as BCR-ABL copies per 10 000 ABL copies, and laboratory G reported absolute values as BCR-ABL per 100 GUS copies (Figure 4a) . When comparing the results between laboratories C and F, and between laboratories D and H, the MRD results were highly concordant for each of these two quantification methods. On application of the CFs the MRD curves became more dispersed within these two groups, however, the overall concordance between results seemed good (sample-specific CV range: 51-99%) (Figure 4b ). The MRD-reporting software includes a formula for expression of MRD data by the DDCt method 11 (Supplementary Table 2 ). When applying this calculation method on text file data from laboratories C, D, F and H, using ABL as the control gene, the sample-specific CV values were at a comparable level (range: 60-77%). However, the smaller mean MRD values by the DDCt method compared with the results expressed at the IS positively affect the size of the CV values, and when comparing samplespecific variation using Levenes test for equality of variances (STATA8, StataCorp LP, College Station, TX, USA) there was better concordance between the laboratories when calculating MRD results with the DDCt method than observed with the CF-adjusted MRD results (Po0.0001) (Figure 4c ). As this finding is based on a restricted number of observations, a more general conclusion on the optimal choice of calculation method for MRD data harmonization would warrant a larger study.
Taken together, the flexible choice between different standard MRD calculation options and the possibility to adjust MRD results by a CF makes the MRD-reporting software highly useful for harmonizing and comparing MRD data between centers.
Discussion
The translation of new technologies from the laboratory bench to the clinical department requires not only formal validation of the method, but, increasingly, also a communicative effort in which data are presented in a meaningful way to the clinician and, ultimately, to the patient. This is, in particular, relevant for cancer patients, in whom disease eradication is far from certain. For hematological malignancies, disease markers have been identified over the course of the last 50 years since the demonstration of the Philadelphia chromosome in CML. 12 Given the existence of such markers, relapses are to an increasing extent detectable in situations where the disease Standardized reporting of MRD data by MRD-reporting software M Østergaard et al Figure 3 Overview of QC I MRD results generated after reanalysis with latest software version. MRD values from the tabular reports were entered in Excel to superimpose the MRD curves for relative and absolute quantification, respectively, for each of the three target genes. y-axis units: absolute quantification: MRD is expressed as BCR-ABL copies/10 000 ABL copies. Relative quantification: MRD is expressed relative to the level in the diagnostic sample. Standardized reporting of MRD data by MRD-reporting software M Østergaard et al has not manifested itself clinically. This underlines the need for a form of data presentation that is as lucid and unequivocal as possible. The software package presented here allows the user to import MRD data from a variety of qPCR platforms. Following this, a database can be created that contains the qPCR data tied together with patient-specific information and necessary details for the actual sample. The software offers a number of choices for data processing in terms of MRD calculation method, graphical display of the MRD values, and layout of the final report to the requesting clinician. The flexibility thus included may be largely expanded upon by the many options to edit program elements that have been granted to the locally appointed software administrator.
The software offers a number of obvious advantages for routine qPCR and MRD applications in terms of data security and storage, as well as streamlining of the work process. From a time-economical point of view, this may be highly valuable, not least for high-throughput laboratories. Moreover, the possibility to easily save and display consecutive control sample data is an important option in terms of quality measures in the laboratory. Because of the built-in data security, the software meets the requirements for prospective accreditation of the MRD application.
We believe that this software may also be an important tool in the context of consolidating the use of MRD assessments for directing treatment of hematological malignancies. Although many laboratories perform qPCR monitoring of MRD in leukemic patients, the data generated have hitherto been mainly descriptive. However, clinical trial initiatives, such as the UK Medical Research Council AML15 study that elucidated treatment of acute promyelocytic leukemia patients based on qPCR detection of PML-RARA transcripts using an internationally standardized method, 13 have now been undertaken in order to validate the implementation of MRD monitoring into clinical decision making.
Our QC study served to provide proof-of-principle of the applicability of the software, and to concomitantly test the software before release within the ELN. To eliminate a major part of the variation to be expected between different laboratories conducting qPCR, identical cDNA samples were used for testing in QC I. In this setting, we observed only a minor qPCR procedure-based variation between the test laboratories. However, when focusing on the clinical relevance of MRD, it was even more important that we were able to demonstrate a parallelism between the MRD curves, as this gives rise to a restricted variation in the fold changes between consecutive samples between the different test laboratories. This finding, which to our knowledge has not previously been elaborated on in a multicenter setting, may be of particular importance in follow-up settings where prognostication after induction therapy or determination of molecular relapse are based on a fold change compared with the previous sample(s). [14] [15] [16] Calculation formulae included in the software can be edited by the user, allowing for adherence to the local standard of expressing MRD results, including reporting the sensitivity afforded by each sample. On the other hand, there is the opportunity to add to the default formulae a correction factor for individual samples, as well as on a general basis, which may be highly relevant in case of assay standardization against a common inter-laboratory reference. In QC II this software feature was tested using a second series of CML samples that were processed according to local procedures and therefore were amenable to application of the CML IS CFs obtained in the five participating laboratories. All laboratories successfully generated reports expressing MRD data according to the CML IS, thereby demonstrating the potential of the program to facilitate the harmonization of multicenter-derived MRD data.
The software includes a formula for relative quantification of MRD by the DDCt method. 11 When we calculated MRD values by this method in the four laboratories in QC II who used ABL as the control gene, we found a very high degree of concordance of the MRD results between the laboratories. This indicates that the DDCt method may represent an alternative method for harmonizing MRD data. Whether this should indeed be the case in CML, as well as in other leukemias will await larger multicenter studies.
As a starting point, we intended to interfere only minimally during the testing process in the laboratories. We found that all laboratories required some degree of support for configuring the software according to local IT systems, whereas in terms of using the software, no help was given. Not surprisingly, we observed a higher success rate of the QC study for the laboratories that had preceding comprehensive or extensive experience with the software compared with the laboratories with no previous experience. However, the requisites for successful use of the software may be built rapidly for new users.
In conclusion, this software is an excellent tool to be used in the daily routine laboratory for calculating and reporting MRD data to clinical use, and an important step in harmonizing the handling of MRD data arising from different qPCR platforms and reporting of the results. This should be of value not only to users at the single institution, but also in the collaborative group setting, which is a prerequisite in these relatively rare cancers, where multicenter studies can be conducted with decentralized performance of MRD determinations.
Perspectives
This software package has been released to all members of the European LeukemiaNet initiative and will be made available to other users. The validation procedures outlined above should make this package suitable for general use in translational hematology allowing standardized reporting of MRD results (eg, use of IS in CML trials), and facilitating comparison of results obtained between trial groups. Indeed the software package is now fully implemented for reporting of MRD data to direct treatment approach in the UK National Cancer Research Institute AML17 trial (http://aml17.cardiff.ac.uk/).
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